Skip to main content
. 2017 Feb 1;78(4):288–294. doi: 10.1055/s-0036-1597834

Table 2. Treatment outcomes.

Treatment outcomes Median (mo) 2 y (%) 3 y (%) 5 y (%) Log-rank p -value
LC
LC according to tumor site Anterior cranial fossa NA 50% (13.7%, 78.5%) 50% (13.7%, 78.5%) NA 0.42
Middle cranial fossa 53.7 (32.8, 60.1) 90.9% (50.8%, 98.7%) 68.2% (16.3%, 92.2%) 45.5% (6.1%, 80.1%)
Posterior cranial fossa NA 63.3% (21.5%, 87.3%) 63.3% (21.5%, 87.3%) 63.3% (21.5%, 87.3%)
Convexity 109.6 (51.8, 167.8) 90.6% (67.3%, 97.6%) 84.1% (57.7%, 94.7%) 74.8% (43.5%, 90.4%)
Parasagittal 46.7 (22.2, 114.3) 88.9% (43.3%, 98.4%) 66.7% (28.17%, 87.8%) 41.7% (10.9%, 70.8%)
Temporal NA 64.3% (15.1%, 90.2%) 64.3% (15.1%, 90.2%) 64.3% (15.1%, 90.2%)
Others NA 50.0% (0.6%, 91.0%) 50.0% (0.6%, 91.0%) NA
LC according to initial symptoms No 53.7 (32.8, 93.1) 78.7% (57.5%, 90.1%) 58.4% (32.5%, 77.3%) 34.1% (7.8%, 63.6%) 0.39
Yes 88.7 (46.7, 167.8) 77.5% (59.9%, 88.1%) 73.6% (55.1%, 85.5%) 64.1% (43.3%, 78.9%)
LC according to age (y) ≤ 60 88.7 (46.7, 167.8) 75.7% (56.8%, 87.2%) 71.3% (51.2%, 84.2%) 65.8% (44.3%, 80.6%) 0.73
> 60 51.8 (32.8, 109.6) 80.4% (60.8%, 90.9%) 64.8% (41.3%, 80.8%) 39.3% (14.7%, 63.4%)
LC according to gender Female 60.1 (37.4, 114.3) 85.9% (68.6%, 94.1%) 75.2% (52.7%, 88.1%) 56.4% (31.4%, 75.4%) 0.59
Male 88.7 (35.0, 167.8) 72.9% (54.1%, 85%) 64.5% (44.2%, 79.1%) 58.1% (36.1%, 74.8%)
LC according to smoking history Never smoker 60.1 (37.4, 167.8) 72.9% (56.6%, 83.9%) 68.9% (51.3%, 81.2%) 54.7% (34.5%, 71%) 0.32
Ever smoker NA 100% (100%, 100%) 75.0% (12.8%, 96.1%) 75.0% (12.8%, 96.1%)
LC according to race White 99.0 (51.8, 167.8) 79.2% (64.5%, 88.4%) 76.6% (61.3%, 86.5%) 60.0% (40.3%, 75%) 0.56
Nonwhite 60.1 (3.1, 60.1) 85.2% (51.9.4%, 96.2%) 63.9% (17.5%, 89.2%) 63.9% (17.5%, 89.2%)
LC according to previous radiation No 60.1 (37.4, 114.3) 79.3% (61.3%, 89.6%) 71.3% (51.3%, 84.2%) 59.1% (35.7%, 76.5%) 0.42
Yes 88.7 (33.3, 167.8) 73.7% (52%, 86.7%) 67.0% (43.0%, 82.7%) 52.1% (26.7%, 72.4%)
LC according to tumor size (cc) < 2 NA 79.1% (51.8%, 92%) 79.1% (51.8%, 92%) 79.1% (51.8%, 92%) 0.59
2–4 60.1 (13.5, 109.6) 80.2% (40.3%, 94.8%) 80.2% (40.3%, 94.8%) 64.2% (22.5%, 87.7%)
4–6 99.0 (4.4, 99.0) 83.3% (27.3%, 97.5%) 62.5% (14.2%, 89.3%) 62.5% (14.2%, 89.3%)
> 6 53.7 (33.3, 167.8) 76.0% (55.7%, 87.9%) 62.6% (40.9%, 78.2%) 46.5% (24.9%, 65.6%)
LC according to radiation dose (Gy) ≤ 13 32.8 (15.0, 114.3) 59.7% (23.5%, 83.2%) 47.8% (15.3%, 74.8%) 17.9% (1.1%, 51.7%) 0.08
> 13 99.0 (51.8, 167.8) 81.9% (68.6%, 90.0%) 73.0% (57.0%, 83.6%) 64.5% (46.0%, 78.1%)
LC according to radiation Rx (mo) ≤ 6 88.7 (51.8, 109.6) 79.4% (50.8%, 92.5%) 79.4% (50.8%, 92.5%) 69.5% (37.5%, 87.4%) 0.98
> 6 99.0 (35.0, 167.8) 75.0% (58.2%, 85.9%) 65.0% (44.7%, 79.4%) 54.2% (28%, 74.5%)
OS
OS according to tumor site Anterior cranial fossa 49.9 (33.5, 64.9) 90.9% (50.8%, 98.7%) 77.9% (35.4%, 94.2%) 46.8% (11.4%, 76.7%) 0.06
Middle cranial fossa 88.1 (34.4, 122.6) 100% (100%, 100%) 80% (20.4%, 96.9%) 80% (20.4%, 96.9%)
Posterior cranial fossa NA 100% (100%, 100%) 100% (100%, 100%) 100% (100%, 100%)
Convexity NA 100% (100%, 100%) 92.3% (56.6%, 98.9%) 92.3% (56.6%, 98.9%)
Parasagittal NA 92.3% (56.6%, 98.9%) 92.3% (56.6%, 98.9%) 92.3% (56.6%, 98.9%)
Temporal NA 75.0% (29.8%, 93.4%) 75.0% (29.8%, 93.4%) 75.0% (29.8%, 93.4%)
Others NA 100% (100%, 100%) 100% (100%, 100%) 66.7% (5.4%, 94.5%)
OS according to initial symptoms No 88.1 (48.3, 122.6) 100% (100%, 100%) 93.3% (61.3%, 99.0%) 84.0% (48.7%, 95.9%) 0.81
Yes NA 90.4% (76.5%, 96.3%) 84.2% (67.9%, 92.7%) 77.6% (59.6%, 88.3%)
OS according to age (y) ≤ 60 NA 97.6% (84.3%, 99.7%) 97.6% (84.3%, 99.7%) 92.2% (69.6%, 98.2%) 0.004
> 60 88.1 (49.9, 122.6) 92.8% (78.4%, 97.7%) 78.9% (57.1%, 90.4%) 68.9% (45.7%, 83.8%)
OS according to gender Female 122.6 (72.8, 122.6) 96.1% (85.2%, 99.0%) 92.1% (75.8%, 97.6%) 82.1% (59.9%, 92.7%) 0.55
Male NA 94.3% (78.6%, 98.6%) 84.9% (63.3%, 94.3%) 80.2% (57.6%, 91.5%)
OS according to smoking history Nonsmokers NA 92.7% (81.3%, 97.3%) 83.1% (66.7%, 91.9%) 71.8% (52.5%, 84.4%) 0.14
Ever smokers NA 100% (100%, 100%) 100% (100%, 100%) 100% (100%, 100%)
OS according to race White NA 93.6% (83.5%, 97.6%) 90.8% (78.5%, 96.2%) 84.7% (69.4%, 92.7%) 0.38
Nonwhite NA 100% (100%, 100%) 71.4% (25.8%, 92.0%) 53.6% (13.2%, 82.5%)
OS according to previous radiation No NA 100% (100%, 100%) 91.7% (70.6%, 97.9%) 91.7% (70.6%, 97.9%) 0.02
Yes NA 87.0% (68.3%, 95.0%) 81.9% (60.6%, 92.3%) 65.0% (40.3%, 81.5%)
OS according to tumor size (cc) < 2 NA 100% (100%, 100%) 88.9% (43.3%, 98.4%) 88.9% (43.3%, 98.4%) 0.64
2–4 NA 100% (100%, 100%) 87.5% (38.7%, 98.1%) 75.0% (31.5%, 93.1%)
4–6 NA 87.5% (38.7%, 98.1%) 87.5% (38.7%, 98.1%) 65.6% (15.7%, 90.9%)
> 6 122.6 (72.8, 173.6) 92.2% (76.9%, 97.5%) 88.2% (70.4%, 95.6%) 83.6% (63.4%, 93.2%)
OS according to radiation dose (Gy) ≤ 13 88.1 (33.5, 122.6) 100% (100%, 100%) 90.0% (47.3%, 98.5%) 80.0% (40.9%, 94.6%) 0.20
> 13 NA 94.1% (84.5%, 97.8%) 88.5% (75.0%, 94.9%) 82.1% (65.8%, 91.1%)
OS according to radiation Rx (mo) ≤ 6 NA 93.9% (77.9%, 98.4%) 93.9% (77.9%, 98.5%) 73.1% (37.2%, 90.5%) 0.78
> 6 NA 95.6% (83.4%, 98.9%) 85.0% (66.9%, 93.7%) 81.3% (62.3%, 91.4%)

Abbreviations: LC, local control; NA, not available; OS, overall survival.

Statistically significant values have been boldfaced.